Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chloramphenicol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.90 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.90 |
| ▸ | RPS17 | P08708 | 1/20 | 0.90 |
| ▸ | RPSA | P08865 | 1/20 | 0.90 |
| ▸ | RPS2 | P15880 | 1/20 | 0.90 |
| ▸ | RPL35A | P18077 | 1/20 | 0.90 |
| ▸ | RPL7 | P18124 | 1/20 | 0.90 |
| ▸ | RPL17 | P18621 | 1/20 | 0.90 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.90 |
| ▸ | RPS3 | P23396 | 1/20 | 0.90 |
| ▸ | RPS12 | P25398 | 1/20 | 0.90 |
| ▸ | RPL13 | P26373 | 1/20 | 0.90 |
| ▸ | RPL10 | P27635 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloramphenicol SCHEMBL4262903 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL28181476 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL49057 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL16111 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL29557257 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL537158 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL11131056 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL41042 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL20531030 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL28607485 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | MMP9, MMP10, MMP17 | LMNA 1476/4885CYP3A4 3597/4885TSHR 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.